Ipratropiumbromid/Salbutamol Neutec (Ipratropium Bromide, Salbutamol)

The product contains two active agents. Ipratropium bromide blocks muscarinic receptors, preventing acetylcholine‑induced airway constriction. Salbutamol stimulates β2‑adrenergic receptors, increasing cyclic AMP and causing smooth‑muscle relaxation. Together they provide additive bronchodilation for faster symptom relief.

The prescribed dose is determined by the treating physician based on the patient’s age, severity of disease, and response to therapy. The prescriber will specify the number of inhalations and frequency according to clinical guidelines.

Safety data in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the prescriber in consultation with the patient.

Enquiries can be submitted on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

The combination offers complementary mechanisms—anticholinergic and β2‑agonist—providing greater bronchodilation than either agent alone. This can result in faster symptom relief and may reduce the need for higher doses of a single drug, potentially lowering side‑effect risk.

Store the inhalation product at room temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme temperatures to maintain potency and device integrity.

The medication is delivered via a metered‑dose inhaler or nebulizer, as directed by the prescriber. Patients should follow the inhalation technique instructions provided with the device to ensure optimal drug deposition in the lungs.

Serious risks include paradoxical bronchospasm, significant tachycardia or arrhythmias, angioedema, and severe allergic reactions. Patients should seek immediate medical attention if they experience difficulty breathing, swelling of the face or throat, or rapid, irregular heartbeats.

The product is contraindicated in individuals with known hypersensitivity to either ipratropium bromide, salbutamol, or any excipients in the formulation. Caution is also advised for patients with certain cardiac conditions, uncontrolled hypertension, or severe arrhythmias.